The Effect of Time-Restricted Feeding on Body Composition and Some Metabolic Parameters in Obese Adolescents
Launched by SÜMEYRA BAŞAR · Sep 24, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of time-restricted feeding on body weight and health in obese adolescents aged 12 to 18. Time-restricted feeding means that participants will have set hours during the day when they can eat, which is thought to help with weight loss and improve metabolic health. The trial aims to compare this method with a Mediterranean diet, which focuses on healthy eating but also limits calorie intake. Researchers hope to find out which method is better for helping adolescents lose weight and improve their health.
To participate, teens must be obese (with a body mass index in the top 5% for their age) and have a related health issue like insulin resistance or fatty liver. They should have been at a stable weight for the last three months and own a smartphone. Participants will be divided into two groups for 12 weeks: one group will follow the time-restricted eating plan, while the other will follow the Mediterranean diet. Throughout the study, researchers will take measurements and blood samples to track changes in body composition and health. This study could provide valuable insights into effective and manageable ways to help adolescents with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adolescents aged 12-18 with puberty stage:5
- • Obese adolescents with a metabolic disorder (such as fatty liver, insulin resistance, prediabetes, dyslipidemia) (BMI≥95th percentile for age)
- • Those who have a stable body weight for 3 months before the start of the study (current weight gain or loss \<4 kg)
- • Those who own and can use a Smartphone with Apple iOS or Android operating system
- • Those who speak, read and understand Turkish
- Exclusion Criteria:
- • Those with any endocrine disorder, metabolic, chronic or major psychiatric disease other than obesity, insulin resistance, dyslipidemia, prediabetes, fatty liver
- • Polycystic ovary syndrome (PCOS)
- • Those with physical or mental disabilities
- • Those with allergies, intolerances or eating disorders
- • Those who smoke and drink alcohol
- • Use of drugs that may affect study results, circadian rhythms or metabolism (such as antidiabetics, steroids, beta blockers, adrenergic stimulating agents, laxatives, etc.)
About Sümeyra Başar
Sümeyra Başar is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative study designs and rigorous methodologies. With a focus on transparency and ethical standards, Sümeyra Başar collaborates with healthcare professionals and research institutions to facilitate the development of cutting-edge therapies. The organization prioritizes patient safety and data integrity, ensuring that all clinical trials are conducted in compliance with regulatory requirements. Through its strategic initiatives, Sümeyra Başar aims to contribute significantly to the scientific community and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kayseri, , Turkey
Patients applied
Trial Officials
Sümeyra Başar
Study Director
sumeyra_akalin@hotmail.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported